alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                       1,389,879
<SECURITIES>                                         0
<RECEIVABLES>                                  262,511
<ALLOWANCES>                                         0
<INVENTORY>                                    521,919
<CURRENT-ASSETS>                             2,237,623
<PP&E>                                         293,397
<DEPRECIATION>                                 248,011
<TOTAL-ASSETS>                               2,323,212
<CURRENT-LIABILITIES>                          192,676
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        34,009
<OTHER-SE>                                   3,147,151
<TOTAL-LIABILITY-AND-EQUITY>                 2,323,212
<SALES>                                        279,928
<TOTAL-REVENUES>                               279,928
<CGS>                                          107,816
<TOTAL-COSTS>                                  107,816
<OTHER-EXPENSES>                               179,341
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,948
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              3,948
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,948
<EPS-PRIMARY>                                      .00
<EPS-DILUTED>                                      .00
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                      17,074,680
<SECURITIES>                                         0
<RECEIVABLES>                                1,829,787
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            18,929,265
<PP&E>                                       8,093,380
<DEPRECIATION>                               (306,204)
<TOTAL-ASSETS>                              28,055,125
<CURRENT-LIABILITIES>                       13,971,952
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     2,141,735
<OTHER-SE>                                  11,941,438
<TOTAL-LIABILITY-AND-EQUITY>                28,055,125
<SALES>                                              0
<TOTAL-REVENUES>                             5,492,692
<CGS>                                                0
<TOTAL-COSTS>                                  848,405
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              4,644,287
<INCOME-TAX>                               (5,360,569)
<INCOME-CONTINUING>                         10,004,856
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                10,004,856
<EPS-PRIMARY>                                     2.33
<EPS-DILUTED>                                        0
        



</TABLE>
[No. 20009-1-II.

Division Two.

December 5, 1997.]

#### The State of Washington, *Respondent,*v. Phillip L. Harmon, *Appellant.*

Appeal from a judgment of the Superior Court for Pierce County, No. 93-1-03445-0, Nile E. Aubrey, J., entered October 16, 1995. *Reversed*by unpublished opinion per Armstrong, J., concurred in by Houghton, C.J., and Bridge-water, J.
§ 522.246 Butorphanol. ( a ) *Specifications.* Each milliliter of solution contains butorphanol (as butorphanol tartrate) in the following amounts: ( 1 ) 0.5 milligrams (mg);
( 2 ) 2 mg; or
( 3 ) 10 mg
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter as follows: ( 1 ) No. 054771 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section; for use of the product described in paragraph (a)(2) as in paragraph (d)(2) of this section; and for use of the product described in paragraph (a)(3) as in paragraph (d)(3) of this section.
( 2 ) No. 043264 for use of the product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
( 3 ) Nos. 000061, 017033, 043264, and 059399 for use of the product described in paragraph (a)(3) of this section as in paragraph (d)(3) of this section.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days.
( ii ) *Indications for use.* For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.
( 2 ) *Cats* — ( i ) *Amount.* Administer 0.2 mg per pound of body weight by subcutaneous injection. Dose may be repeated up to 4 times per day. Do not treat for more than 2 days.
( ii ) *Indications for use.* For the relief of pain in cats caused by major or minor trauma, or pain associated with surgical procedures.
( 3 ) *Horses* — ( i ) *Amount.* Administer 0.05 mg per pound of body weight by intravenous injection. Dose may be repeated within 3 to 4 hours. Treatment should not exceed 48 hours.
( ii ) *Indications for use.* For the relief of pain associated with colic and postpartum pain in adult horses and yearlings.
( iii ) *Limitations.* Do not use in horses intended for human consumption.
[72 FR 27957, May 18, 2007, as amended at 73 FR 31358, June 2, 2008; 74 FR 61516, Nov. 25, 2009; 75 FR 22524, Apr. 29, 2010; 77 FR 60302, Oct. 3, 2012; 78 FR 17597, Mar. 22, 2013; 79 FR 16184, Mar. 25, 2014; 79 FR 74020, Dec. 15, 2014; 80 FR 13229, Mar. 13, 2015; 87 FR 17945, Mar. 29, 2022; 88 FR 16547, Mar. 20, 2023]
UNPUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 08-6447

GREGORY RICE,
Plaintiff - Appellant,

v.
STATE OF MARYLAND, in and for Washington County; FRED C. WRIGHT, III; DONALD EUGENE BEACHLEY; DON MCDOWELL; CHARLES STRONG; DANA MAYLAN, Ethics Commission; JOHN BARR, President, Commissioner,

Defendants - Appellees.

Appeal from the United States District Court for the District of Maryland, at Baltimore. Peter J. Messitte, Senior District Judge. (8:08-cv-00590-PJM)

Submitted: September 28, 2009 Decided: October 22, 2009

Before MOTZ and DUNCAN, Circuit Judges, and HAMILTON, Senior Circuit Judge.

Affirmed by unpublished per curiam opinion.

Gregory Rice, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM:
Gregory Rice appeals the district court’s order

construing his 42 U.S.C. § 1983 (2006) complaint as a petition

for writ of mandamus and dismissing it without prejudice. ∗ We

have reviewed the record and find no reversible error. Although

the district court did not specifically address Rice’s claim of

the denial of access to courts, we find that the claim fails

because the defendants are immune from suit. Stump v. Sparkman ,
435 U.S. 349, 356-57 (1978); King v. Myers , 973 F.2d 354, 356-57
(4th Cir. 1992). Accordingly, we affirm. We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would

not aid the decisional process.

AFFIRMED

∗ Generally, dismissals without prejudice are interlocutory and not appealable. Domino Sugar Corp. v. Sugar Workers Local Union 392 , 10 F.3d 1064, 1066 (4th Cir. 1993). However, a dismissal without prejudice could be final if no amendment to the complaint could cure the defects in the plaintiff’s case. Id. at 1066-67. We conclude that the defects in this case cannot be cured by an amendment to the complaint and that the order is therefore appealable.
I 

118TH CONGRESS 

2D SESSION H. R. 7485 

To amend section 13105(l) of title 5, United States Code, to require the 

reporting of periodic transaction reports not later than 24 hours after 

receiving notification of the requirement to report a transaction but 

in no case later than 72 hours after such transaction. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 29, 2024 

Mr. BURCHETT introduced the following bill; which was referred to the Committee on Oversight and Accountability, and in addition to the Committees on House Administration, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of 

such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend section 13105(l) of title 5, United States Code, 

to require the reporting of periodic transaction reports 

not later than 24 hours after receiving notification of 

the requirement to report a transaction but in no case 

later than 72 hours after such transaction. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Immediate Stock Dis5 closure Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7485 IH

1 SEC. 2. PERIODIC TRANSACTION REPORTS. 

2 Section 13105(l) of title 5, United States Code, is 

3 amended by— 

4 (1) striking ‘‘30 days’’ and inserting ‘‘24 

5 hours’’; and 

6 (2) striking ‘‘45 days’’ and inserting ‘‘72 

7 hours’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Exhibit 21.1

SUBSIDIARIES

DOMESTIC SUBSIDIARIES OF THE COMPANY:

Name of Subsidiary


State of
IncorporationPCT International Holdings Inc.


DelawareFlavors Holdings Inc.


DelawareMafco Worldwide Corporation


DelawareMafco Shanghai Corporation


DelawareEVD Holdings Inc.


DelawarePneumo Abex LLC


DelawareConcord Pacific Corporation


MainePneumo Abex Lessee Corp.


DelawareCA Acquisition Holdings Inc.


DelawareHarland Clarke Holdings Corp.


DelawareHarland Clarke Corp.


DelawareChecks in the Mail, Inc.


DelawareHFS Scantron Holdings Corp.


New YorkScantron Corporation


DelawareHarland Financial Solutions, Inc.


OregonJohn H. Harland Company of Puerto Rico


GeorgiaCentralia Holdings Corporation


Georgia


FOREIGN SUBSIDIARIES OF THE COMPANY:

Name of Subsidiary


JurisdictionEVD Holdings S.A.


FranceExtraits Vegetaux Et Derives, S.A.


FranceWei Feng Enterprises Ltd.


British Virgin IslandsXianyang Concord Natural Products Co. Ltd.


People’s Republic of ChinaZhangjiagang Free Trade Zone MAFCO Liantai Biotech Co., Ltd.


People’s Republic of ChinaMafco Weihai Green Industry of Science and Technology Co. Ltd. (40% owned)


People’s Republic of ChinaScantron Canada, Ltd.


CanadaHarland Israel Ltd.


IsraelHarland Financial Solutions Worldwide Limited


Ireland


---
Exhibit 31.1

                                  CERTIFICATION

I, Kwok Leung Li, certify that:

1. I have reviewed this Form 10-KSB of LMIC, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

b. Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

c. Disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

Date: October 18, 2004


By: /s/ Kwok Leung Li
-----------------------
Kwok Leung Li
Chief Executive Officer
```

[115th Congress Public Law 292]
[From the U.S. Government Publishing Office]

[[Page 132 STAT. 4376]]

Public Law 115-292
115th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
    4801 West Van Giesen Street in West Richland, Washington, as the 
 ``Sergeant Dietrich Schmieman Post Office Building''. <<NOTE: Dec. 6, 
                         2018 -  [H.R. 5504]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SERGEANT DIETRICH SCHMIEMAN POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 4801 West Van Giesen Street in West Richland, Washington, 
shall be known and designated as the ``Sergeant Dietrich Schmieman Post 
Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Sergeant 
Dietrich Schmieman Post Office Building''.

    Approved December 6, 2018.

LEGISLATIVE HISTORY--H.R. 5504:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 164 (2018):
            July 16, considered and passed House.
            Nov. 15, considered and passed Senate.

                                  <all>
```
## Good Neighbor Environmental Board **Double Tree by Hilton Hotel El Paso Downtown** 

**600 North El Paso Street El Paso, Texas 79901**  

## AGENDA **Thursday, June 2** **8** 8 :0 0 a.m . **Registration** 8 :3 0 -8 : 45 **Welcome and Introductions**

 **Mark Joyce** Associate Director and Acting Designated Federal Officer Office of Federal Advisory Committee Management and Outreach

 **Diane Austin** Chair Good Neighbor Environmental Board 8 : 45 - 10: 00 **Environment and Water**  **Quality**  Aimee Roberson – Transboundary Conservation of Rio Grande Watershed and the Big Bend - Rio Bravo Region U.S. Fish and Wildlife Service

 Leslie Grijalva – Rio Grande Water Quality Texas Clean Rivers Program, International Boundary and Water Commission

 Omar Chacón Betancourt Chief, Department of Regulation and Sanitation, Junta Municipal de Agua y Saneamiento (Municipal Board of Water and Sanitation) 10: 00 - 10: 1 5 **Break** 10: 1 5 - 1 1 : 30 **Water Supply**  **Perspectives**  Jesus Reyes – Local Water Management General Manager, El Paso County Water Improvement District # 1

 Jesus Reyes – Regional Approach and Challenges Paso del Norte Carlos Peña – Transboundary Aquifer Assessment Program Principal Engineer, International Boundary and Water Commission 11:30- 12:15 **Reso urces**   Doug Liden - Border 2020 Update Environmental Protection Agency, Region 9

 Maria Elena Giner - BECC Update General Manager, Border Environment Cooperation Commission 12 : 15 - 12: 45 **Public Comments**  12 : 45 - 1 : 45 **Lunch** 1 : 45 -3: 00 **Discussion of 1 5**  **th Report**  3: 0 0-3: 1 5 **Break** 4:00- 6:00 **Discussion of 1**  **5 th**  **Report** 6 : 0 0 **Adjourn Meeting Day 2**  **Friday, June 29**  8:30-9:3 0 **Discussion of Next Meetings and Other Business**  9:30- 11:00 **Discussion of 1**  **5 th**  **Report** 11:00- 11:15 **Break** 11:15 - 1:30 **Discussion of 1**  **5 th**  **Report** 1 :30-2 :00 **Public Comments** 2 :00 **Adjourn**
*

 Pursuant to Local Rule 47.5, the court has determined that this opinion should not be

published and is not precedent except underthe limited circumstancessetforth inLocalRule

47.5.4.

UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 96-40738

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

VICTOR AGUILAR, a/k/a Mondo,

Defendant-Appellant.

Appeal from the United States District Court

For the Southern District of Texas

(L-96-CR-29-2)

February 19, 1997

Before POLITZ, Chief Judge, WIENER and EMILIO M. GARZA, Circuit Judges.

PER CURIAM:*

This matter is before the court on appeal by Victor Aguilar of his ten-year

mandatory minimum sentence on a guilty plea to possession with intent to
1

 386 U.S. 738 (1967).

2

distribute over 1000 pounds of marihuana in violation of 21 U.S.C. § 841(a)(1),

enhanced by a prior state felony drug conviction. Court-appointed counsel for the

defendant has filed a brief pursuant to the directives of Anders v. California1and

has moved to be relieved from further responsibilities herein.

Our independent review of the briefs and record discloses no issue of merit

to be addressed on appeal. Accordingly, the motion of counsel to withdraw is

GRANTED and the appeal of Victor Aguilar is DISMISSED.
**EXHIBIT 12****Republic Bancorp Inc.****Calculations of Ratios of Earnings to Combined Fixed Charges****Three Months Ended**



**Nine Months Ended**(in thousands)

**September 30,**


**September 30,****2004**



**2003**



**2004**



**2003****Including Interest on Deposits:**Fixed charges:Total interest expense

$
33,591




$
30,150




$
97,326




$
92,352Interest portion of rent expense


190





188





567





569Fixed charges including interest on deposits

$
33,781




$
30,338




$
97,893




$
92,921Earnings:Net income

$
17,213




$
15,790




$
49,880




$
46,101Income taxes


6,738





6,523





20,578





19,877Fixed charges, as above


33,781





30,338





97,893





92,921Earnings for purposes of calculation

$
57,732




$
52,651




$
168,351




$
158,899Ratio of earnings to combined fixed charges includinginterest on deposits


1.71


x


1.74


x


1.72


x


1.71


x**Excluding Interest on Deposits:**Fixed charges:Total interest expense excluding interest on deposits

$
20,567




$
16,978




$
58,598




$
49,254Interest portion of rent expense


190





188





567





569Fixed charges excluding interest on deposits

$
20,757




$
17,166




$
59,165




$
49,823Earnings:Net income

$
17,213




$
15,790




$
49,880




$
46,101Income taxes


6,738





6,523





20,578





19,877Fixed charges, as above


20,757





17,166





59,165





49,823Earnings for purposes of calculation

$
44,708




$
39,479




$
129,623




$
115,801Ratio of earnings to combined fixed charges excludinginterest on deposits


2.15


x


2.30


x


2.19


x


2.32


x
PUBLIC LAW 115–285—DEC. 6, 2018 132 STAT. 4369 

LEGISLATIVE HISTORY—H.R. 2979: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

July 16, considered and passed House. 

Nov. 15, considered and passed Senate. 

Æ 

Public Law 115–285 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 390 West 

5th Street in San Bernardino, California, as the ‘‘Jack H. Brown Post Office 

Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. JACK H. BROWN POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 390 West 5th Street in San Bernardino, California, shall be known and designated as the ‘‘Jack H. Brown 

Post Office Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Jack H. Brown Post Office Building’’. 

Approved December 6, 2018. 

Dec. 6, 2018 

[H.R. 2979] 


ralbany on LAP520R082 with PUB LAWS PDF
#### § 520.1805 Piperazine phosphate with thenium closylate tablets.

(a) *Specifications.* Each scored tablet contains the equivalent of 250 milligrams piperazine hexahydrate (as piperazine phosphate) and 125 milligrams thenium (as thenium closylate) or 500 milligrams piperazine hexahydrate (as piperazine phosphate) and 250 milligrams thenium (as thenium closylate).

(b) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.

(c) *Conditions of use* —

(1) *Amount.* Administer orally to dogs as follows:

| Animal weight (lb) | 375 mg | 750 mg |
| --- | --- | --- |
| 2 but less than 5 | 1/2 | |
| 5 but less than 10 | 1 | 1/2 |
| 10 or heavier | 2 | 1 |

Number of Tablets at Each of the Two Doses

(2) *Indications for use.* For removal of immature (fourth stage larvae) and adult hookworms (*Ancylostoma caninum, A. braziliense,* and *Uncinaria stenocephala*) and ascarids (*Toxocara canis*) from weaned pups and adult dogs.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[43 FR 32747, July 28, 1978, as amended at 47 FR 55476, Dec. 10, 1982; 61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997; 78 FR 28826, May 20, 2014]